SENATE BILL 249

53rd legislature - STATE OF NEW MEXICO - second session, 2018

INTRODUCED BY

Bill B. O'Neill

AN ACT

RELATING TO PHARMACEUTICALS; AMENDING A SECTION OF THE CONTROLLED SUBSTANCES ACT TO EXEMPT FROM PROSECUTION CERTAIN ACTIVITIES RELATING TO PRESCRIPTION DRUGS CONTAINING A MARIJUANA DERIVATIVE; PROVIDING FOR A CONTINGENT EFFECTIVE DATE; AUTHORIZING RECONCILIATION OF MULTIPLE AMENDMENTS TO THE SAME SECTION OF LAW.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

     SECTION 1. Section 30-31-6 NMSA 1978 (being Laws 1972, Chapter 84, Section 6, as amended) is amended to read:

     "30-31-6. SCHEDULE I.--The following controlled substances are included in Schedule I:

          A. any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically exempted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

                (1) acetylmethadol;

                (2) allylprodine;

                (3) alphacetylmethadol;

                (4) alphameprodine;

                (5) alphamethadol;

                (6) benzethidine;

                (7) betacetylmethadol;

                (8) betameprodine;

                (9) betamethadol;

                (10) betaprodine;

                (11) clonitazene;

                (12) dextromoramide;

                (13) dextrorphan;

                (14) diampromide;

                (15) diethylthiambutene;

                (16) dimenoxadol;

                (17) dimepheptanol;

                (18) dimethylthiambutene;

                (19) dioxaphetyl butyrate;

                (20) dipipanone;

                (21) ethylmethylthiambutene;

                (22) etonitazene;

                (23) etoxeridine;

                (24) furethidine;

                (25) hydroxypethidine;

                (26) ketobemidone;

                (27) levomoramide;

                (28) levophenacylmorphan;

                (29) morpheridine;

                (30) noracymethadol;

                (31) norlevorphanol;

                (32) normethadone;

                (33) norpipanone;

                (34) phenadoxone;

                (35) phenampromide;

                (36) phenomorphan;

                (37) phenoperidine;

                (38) piritramide;

                (39) proheptazine;

                (40) properidine;

                (41) racemoramide; and

                (42) trimeperidine;

          B. any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically exempted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

                (1) acetorphine;

                (2) acetyldihydrocodeine;

                (3) benzylmorphine;

                (4) codeine methylbromide;

                (5) codeine-N-oxide;

                (6) cyprenorphine;

                (7) desomorphine;

                (8) dihydromorphine;

                (9) etorphine;

                (10) heroin;

                (11) hydromorphinol;

                (12) methyldesorphine;

                (13) methyldihydromorphine;

                (14) morphine methylbromide;

                (15) morphine methylsulfonate;

                (16) morphine-N-oxide;

                (17) myrophine;

                (18) nicocodeine;

                (19) nicomorphine;

                (20) normorphine;

                (21) pholcodine; and

                (22) thebacon;

          C. any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically exempted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

                (1) 3,4-methylenedioxy amphetamine;

                (2) 5-methoxy-3,4-methylenedioxy amphetamine;

                (3) 3,4,5-trimethoxy amphetamine;

                (4) bufotenine;

                (5) diethyltryptamine;

                (6) dimethyltryptamine;

                (7) 4-methyl-2,5-dimethoxy amphetamine;

                (8) ibogaine;

                (9) lysergic acid diethylamide;

                (10) marijuana;

                (11) mescaline;

                (12) peyote, except as otherwise provided in the Controlled Substances Act;

                (13) N-ethyl-3-piperidyl benzilate;

                (14) N-methyl-3-piperidyl benzilate;

                (15) psilocybin;

                (16) psilocyn;

                (17) tetrahydrocannabinols;

                (18) hashish;

                (19) synthetic cannabinoids, including:

                     (a) 1-[2-(4-(morpholinyl)ethyl]

-3-(1-naphthoyl)indole;

                     (b) 1-butyl-3-(1-napthoyl)indole;

                     (c) 1-hexyl-3-(1-naphthoyl)indole;

                     (d) 1-pentyl-3-(1-naphthoyl)indole;

                     (e) 1-pentyl-3-(2-methoxyphenylacetyl) indole;

                     (f) cannabicyclohexanol (CP 47, 497 and homologues: 5-(1,1-dimethylheptyl)-2-[(1R,3S)

-3-hydroxycyclohexyl]-phenol (CP-47,497); and 5-(1,

1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

                     (g) 6aR,10aR)-9-(hydroxymethyl)

-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,

10a-tetrahydrobenzo[c]chromen-1-ol);

                     (h) dexanabinol, (6aS,10aS)

-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)

-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

                     (i) 1-pentyl-3-(4-chloro naphthoyl) indole;

                     (j) (2-methyl-1-propyl-1H-indol-3-yl)

-1-naphthalenyl-methanone; and

                     (k) 5-(1,1-dimethylheptyl)-2-(3-hydroxy cyclohexyl)-phenol;

                (20) 3,4-methylenedioxymethcathinone;

                (21) 3,4-methylenedioxypyrovalerone;

                (22) 4-methylmethcathinone;

                (23) 4-methoxymethcathinone;

                (24) 3-fluoromethcathinone; and

                (25) 4-fluoromethcathinone;

          D. the enumeration of peyote as a controlled substance does not apply to the use of peyote in bona fide religious ceremonies by a bona fide religious organization, and members of the organization so using peyote are exempt from registration. Any person who manufactures peyote for or distributes peyote to the organization or its members shall comply with the federal Comprehensive Drug Abuse Prevention and Control Act of 1970 and all other requirements of law;

          E. the enumeration of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol as Schedule I controlled substances does not apply to:

                (1) the use of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol by certified patients pursuant to the Controlled Substances Therapeutic Research Act or by qualified patients pursuant to the provisions of the Lynn and Erin Compassionate Use Act; [and] or

                (2) the use, dispensing, possession, prescribing, storage or transport of a prescription drug that the United States food and drug administration has approved and that contains marijuana, a tetrahydrocannabinol derivative or a chemical derivative of tetrahydrocannabinol; and

          F. controlled substances added to Schedule I by rule adopted by the board pursuant to Section 30-31-3 NMSA 1978."

     SECTION 2. TEMPORARY PROVISION--COMPILATION INSTRUCTION--RECONCILIATION.--If acts making amendments to Section 30-31-6 NMSA 1978 are enacted by the first and second sessions of the fifty-third legislature, the provisions of those acts shall be reconciled and compiled in accordance with the provisions of Section 12-1-8 NMSA 1978, notwithstanding that the amendments were not made in the same session of the legislature.

     SECTION 3. CONTINGENT EFFECTIVE DATE--NOTIFICATION.--The effective date of the provisions of this act is thirty days following the date that the board of pharmacy certifies to the New Mexico compilation commission and the director of the legislative council service that the United States food and drug administration has approved one or more drugs containing a marijuana derivative. The board of pharmacy shall notify the New Mexico compilation commission and the director of the legislative council service immediately upon the board's knowledge that the United States food and drug administration has approved for the first time a drug containing a marijuana derivative.

- 8 -